Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Synthetic Lethal Screen for Breast Cancer 1 (BRCA1)-Deficient Cancers

FY 2017-18

Summary
The breast cancer susceptibility gene 1 (BRCA1) gene encodes a protein which functions to maintain genomic integrity. Mutations in BRCA1 are associated with increased risk of developing breast (≥80%) and ovarian (≥40%) cancers. Additionally, tumors arising from BRCA1 mutations are typically high grade and recurrent in nature. Therefore, specifically targeting tumors that arise from BRCA1 mutations is of great interest. One method by which this could be accomplished relies on the principle of synthetic lethality, which refers to the loss of viability resulting from the disruption of two genes, which, individually, does not cause lethality. Poly (ADP-ribose) polymerase (PARP) has been shown to have a synthetic lethal relationship with BRCA1, and thus has garnered interest as a potential therapeutic target. Although PARP inhibitors (PARPi) have been granted FDA approval for monotherapy in patients with germline mutations of BRCA1 , tumor resistance to PARPi have been reported. Thus, there is an urgent need to develop new therapies to target these class of cancers. We propose a synthetic lethal screen to identify novel susceptibilities in BRCA1-deficient breast cancers. The screen will employ CRISPR/Cas9 technology to effectively and specifically delete genes in multiple breast cancer cell lines with varying expression profiles of BRCA1. Furthermore, our library specifically targets genes for which there are FDA-approved drugs. Therefore, our study would permit speedy transition to pre-clinical models and, ultimately, to patients. Given that mutations of BRCA1 are not exclusive to breast and ovarian cancer, our findings can be extended to the study and treatment of various other cancers including cancer of the prostate and pancreas.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
386674
Name
Algouneh Arash
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Synthetic Lethal Screen for Breast Cancer 1 (BRCA1)-Deficient Cancers
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Crispr Screen; Crispr/Cas9; Fda Approved Drugs; Genomic Instability; Homologous Recombination; Lentivirus Transduction; Synthetic Lethality
Abstract
The breast cancer susceptibility gene 1 (BRCA1) gene encodes a protein which functions to maintain genomic integrity. Mutations in BRCA1 are associated with increased risk of developing breast (≥80%) and ovarian (≥40%) cancers. Additionally, tumors arising from BRCA1 mutations are typically high grade and recurrent in nature. Therefore, specifically targeting tumors that arise from BRCA1 mutations is of great interest. One method by which this could be accomplished relies on the principle of synthetic lethality, which refers to the loss of viability resulting from the disruption of two genes, which, individually, does not cause lethality. Poly (ADP-ribose) polymerase (PARP) has been shown to have a synthetic lethal relationship with BRCA1, and thus has garnered interest as a potential therapeutic target. Although PARP inhibitors (PARPi) have been granted FDA approval for monotherapy in patients with germline mutations of BRCA1 , tumor resistance to PARPi have been reported. Thus, there is an urgent need to develop new therapies to target these class of cancers. We propose a synthetic lethal screen to identify novel susceptibilities in BRCA1-deficient breast cancers. The screen will employ CRISPR/Cas9 technology to effectively and specifically delete genes in multiple breast cancer cell lines with varying expression profiles of BRCA1. Furthermore, our library specifically targets genes for which there are FDA-approved drugs. Therefore, our study would permit speedy transition to pre-clinical models and, ultimately, to patients. Given that mutations of BRCA1 are not exclusive to breast and ovarian cancer, our findings can be extended to the study and treatment of various other cancers including cancer of the prostate and pancreas.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Algouneh, Arash
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~